
ImmuPharma Investor Relations Material
Latest events

H2 2024
19 May, 2025

H1 2024
9 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmuPharma plc
Access all reports
ImmuPharma plc is a pharmaceutical company focused on the research, development, and commercialization of novel peptide-based drugs. The company specializes in therapies for autoimmune and inflammatory diseases, with activities spanning early-stage discovery through to clinical development. Its research is supported by collaborations with scientific institutions and licensing partnerships. The company is headquartered in London, United Kingdom, and its shares are listed on the AIM.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
IMM
Country
🇬🇧 United Kingdom